JAMA Oncology : Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

JAMA Network
24/10/2024 20 min
JAMA Oncology : Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

Listen "JAMA Oncology : Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma"

Descargar episodio Ver en sitio original

Episode Synopsis

Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

More episodes of the podcast JAMA Network

JAMA Otolaryngology–Head & Neck Surgery : Why Hearing Health Must Be Part of Voice Biomarker Research 02/01/2026
JAMA Ophthalmology : Aflibercept Dose in Polypoidal Choroidal Vasculopathy 18/12/2025
JAMA Psychiatry : Tailored Weight Loss Programs for Adults With Serious Mental Illness 17/12/2025
JAMA Surgery : Mortality Among Surgeons in the United States 17/12/2025
JAMA Ophthalmology : The Central Role of Home Hazards in Shaping the Association of Visual Function and Falls in Older Adults 11/12/2025
JAMA Otolaryngology–Head & Neck Surgery : Biofeedback vs Respiratory Retraining for Inducible Laryngeal Obstruction 11/12/2025
JAMA Cardiology : Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement 10/12/2025
JAMA Internal Medicine : Magnesium Supplementation and Tachyarrhythmias 08/12/2025
JAMA Surgery : Diagnosis and Management of Hemodialysis Access Complications 03/12/2025
JAMA Oncology : Metastatic Recurrence Among Adolescents and Young Adults With Cancer 26/11/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA